Navigation Links
AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia
Date:4/15/2008

QUEBEC CITY, April 15 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported the completion of patient recruitment for the Company's first efficacy trial of its Phase 3 program in benign prostatic hyperplasia (BPH), a non-cancerous enlargement of the prostate, with its flagship product candidate, cetrorelix. The study involves approximately 600 patients primarily in the United States and Canada, with additional sites in Europe.

"We are very proud to have reached this important milestone. The Phase 3 program in BPH with cetrorelix is on track and we expect to provide results in the third quarter of 2009 as stated previously," commented Paul Blake, M.D., Senior Vice President and Chief Medical Officer of AEterna Zentaris.

This first efficacy study, titled "Cetrorelix pamoate intermittent IM dosage regimens in patients with symptomatic BPH: a 1-year placebo-controlled efficacy study and long-term safety assessment", will assess an intermittent dosage regimen of cetrorelix as a safe and tolerable treatment providing prolonged improvement in BPH-related signs and symptoms.

About the Phase 3 Program with Cetrorelix in BPH

The first multi-center efficacy study commenced first patient randomization in April 2007 and completion of patient recruitment was announced today. It is currently being conducted primarily in the United States and Canada, with additional sites in Europe and involves approximately 600 patients under the supervision of lead investigator, Herbert Lepor, MD, Professor at NY University School of Medicine, New York. Patients enter a 4-week run-in no-treatment observation period to confirm sever
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris Announces Changes to its Management Team
2. AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights
3. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
4. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
5. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
6. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
9. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
10. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
11. AEterna Zentaris Announces Outcome of Managements Strategic Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... XenoTech announces an exclusive partnership with ... from bioactive small molecules. Based on an ... convenient and timely assessment of critical metabolite and ... of Commercial Operations, Christian Darabant, “the value of ... be measured directly by comparison with the approximate ...
(Date:8/19/2014)... CSSi, the leader in patient recruitment solutions ... of the company,s Medical and Clinical Advisory Board ("MCAB") ... William E. Gannon, Jr. to the MCAB. ... The MCAB, with Dr. Gannon,s leadership, will help ... set strategic goals for the advancement and development of ...
(Date:8/19/2014)... ROCKVILLE, Md. , Aug. 19, 2014 /PRNewswire/ ... a biotechnology company developing novel anti-infective biologic and ... infections and diseases, announced today that its novel ... highlighted at the 54 th Interscience Conference ... in Washington D.C. ...
(Date:8/19/2014)... Sales Horizons, a leader in sales ... sales skills training course to help companies develop ... staff spend the majority of their time on client ... or physician practice – providing support and education to ... Sales Horizons believes clinical staff are and should be ...
Breaking Biology Technology:Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3
... powered by ForceLogix, on-demand technology, wins Ventana ... and BRACKNELL, U.K., Nov. 12 ForceLogix ... Operational Performance,Leadership Award for Sales, honoring the ... and technology for optimal sales,business impact. ...
... /Xinhua-PRNewswire-FirstCall/ -- Discas, Inc. (Pink,Sheets: DSCS.PK), ("the Company") ... into a stock purchase agreement with SNX Organic ... is Beijing Shen,Nong Xing Technology Co. Ltd. ("BSNX"), ... in the research and development of,green and organic ...
... Lev Pharmaceuticals, Inc.,(OTC Bulletin Board: LEVP.OB) today announced that it will conduct a,conference ... Time (ET), in conjunction with the release of its financial,results for the third ... ET on Tuesday, November 13,2007. DATE: ... 1PM ET ...
Cached Biology Technology:ForceLogix, Innovex Win Sales Operational Performance Award 2ForceLogix, Innovex Win Sales Operational Performance Award 3Discas, Inc. Sells Shares to SNX Organic Fertilizers, Inc. 2Lev Pharmaceuticals Invites You to Participate in its Q3'07 Earnings Results Conference Call and Webcast 2
(Date:8/20/2014)... are athletes who have suffered concussions ready to return ... found that high school athletes who head back on ... a significant regression in their abilities to simultaneously walk ... seen in changes in their balance and/or altered walking ... of the 12 had returned to activity in less ...
(Date:8/20/2014)... 2014) Women who are poor experience higher cortisol ... elevated levels of the stress hormone, putting them ... according to a new research from the University of ... the American Journal of Human Biology , is ... it directly to the socioeconomic status of their mothers ...
(Date:8/20/2014)... and POINT ROBERTS, Washington , ... Play a Key Role in Addressing Security Concerns in the ... a global news source covering leading sectors including biometrics, issues ... market. Jason Peaslee , Managing Partner at ... and Gino Pereira , CEO of NXT-ID, Inc. (OTCBB: ...
Breaking Biology News(10 mins):Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3CU Denver researcher shows economic disparities impact infant health 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 3Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 4Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 5Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 6Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 7
... from the talents of Rembrandt, Van Gogh and other ... of colors on a palette. In a similar manner, ... (NIST) have created an innovative device called the "microfluidic ... concentration across an areain a miniature chamber about the ...
... WINSTON-SALEM Rates of severe childhood obesity have tripled in ... diabetes and heart disease, according to a report in ... Hospital, part of Wake Forest University Baptist Medical Center. ... obese, which impacts their overall health," said Joseph Skelton, M.D., ...
... Large trees have declined in Yosemite National Park ... play a role. The number of large-diameter trees ... and 1990s. U.S. Geological Survey and University of Washington ... from 1932� to the most recent records from 1988�. ...
Cached Biology News:'Microfluidic palette' may paint clearer picture of biological processes 2Research shows rates of severe childhood obesity have tripled 2
... Inhibitors have broad spectrum RNase inhibitory properties, ... the neutral type (1). The 50kDa protein ... to RNases in a 1:1 ratio. The ... Ribonuclease Inhibitor to RNase (e.g., RNase A) ...
...
Canine Aortic Smooth Muscle Cells (CnAOSMC) (>500,000 cells)...
... For nucleofection of optimized cell lines ... including the nucleofection parameters. Nucleofector Kits are ... Device., Different cell lines can be transfected ... viabilities are given in brackets in percent ...
Biology Products: